Related Experiment Videos
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist
Fabio Canino1, Claudia Omarini2, Krisida Cerma1
1Division of Medical Oncology, Deptartment of Medical and Surgical Sciences for Children and Adults - University Hospital of Modena, Italy.
Abstract:
Ocular adverse events are common to many antineoplastic agents, although often misunderstood. In most cases, they are easily manageable, but sometimes they require instrumental diagnostics and specific treatments. There are currently no international guidelines for the management of these toxicities. In this review we summarized the main ocular adverse events related to the antineoplastic agents used in the treatment of breast cancer, analyzing their clinical presentation and management, trying to provide a useful tool to be used in clinical practice.
Insights
Ocular adverse events from antineoplastic agents are common but manageable. This review details their presentation and treatment for breast cancer patients, offering a clinical practice guide.
Area of Science:
- Oncology
- Ophthalmology
- Pharmacology
Background:
- Antineoplastic agents are crucial for breast cancer treatment.
- Ocular adverse events are frequent but often poorly understood.
- Current management lacks international guidelines.
Purpose of the Study:
- To review ocular adverse events associated with breast cancer antineoplastic agents.
- To analyze clinical presentation and management strategies.
- To provide a practical tool for clinicians.
Main Methods:
- Literature review of ocular toxicities.
- Analysis of antineoplastic agents used in breast cancer.
- Synthesis of clinical presentation and management data.
Main Results:
- Identified common ocular adverse events.
- Described clinical manifestations and diagnostic approaches.
- Outlined management and treatment options.
Conclusions:
- Ocular adverse events require specific attention.
- Standardized management protocols are needed.
- This review serves as a clinical resource for managing these toxicities.